e-learning
resources
Berlin 2001
Sunday 23.09.2001
Lung cancer diagnosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis
A. Guber, D. Yam, R. Shainkin-Kestenbaum, M. Lis, D. Nabriski, Y. Smorzik (Kfar Saba, Rehovot, Israel)
Source:
Annual Congress 2001 - Lung cancer diagnosis
Session:
Lung cancer diagnosis
Session type:
Thematic Poster Session
Number:
511
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Guber, D. Yam, R. Shainkin-Kestenbaum, M. Lis, D. Nabriski, Y. Smorzik (Kfar Saba, Rehovot, Israel). Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis. Eur Respir J 2001; 16: Suppl. 31, 511
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 82s
Year: 2004
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 251s
Year: 2003
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)?
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020
The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC)
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
Serum tumor markers in lung cancer patients
Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies
Year: 2007
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
Source: Eur Respir J 2010; 36: 885-892
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept